Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2016 12/02/2016 12/05/2016 12/06/2016 12/07/2016 Date
375.56(c) 372.71(c) 369.82(c) 368.95(c) 362.01(c) Last
824 192 723 571 661 740 725 388 1 681 353 Volume
-0.97% -0.76% -0.78% -0.24% -1.88% Change
More quotes
Financials ($)
Sales 2016 4 943 M
EBIT 2016 1 849 M
Net income 2016 887 M
Finance 2016 668 M
Yield 2016 -
Sales 2017 5 751 M
EBIT 2017 2 255 M
Net income 2017 1 107 M
Finance 2017 1 039 M
Yield 2017 -
P/E ratio 2016 47,39
P/E ratio 2017 39,06
EV / Sales2016 7,59x
EV / Sales2017 6,46x
Capitalization 38 181 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
12/02 Pharma execs weigh in on possible changes under Trump
11/30 REGENERON PHARMACEUTICALS : Curable working on its biggest genetic sequencing pr..
11/25 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Termination of a Mater..
11/25 REGENERON PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (..
11/24 REGENERON PHARMACEUTICALS : Assigned Patent
11/22 REGENERON PHARMACEUTICALS : and Sanofi to Present Data from Phase 3 Praluent® al..
11/22 REGENERON PHARMACEUTICALS : Patent Application Titled "Universal Plunger Rods, S..
11/22 REGENERON PHARMACEUTICALS : and Sanofi Announce Praluent® alirocumab Cardiovascu..
11/22 REGENERON PHARMACEUTICALS : Curable Initiates the International PSC Genome Proje..
11/22 REGENERON PHARMACEUTICALS : New Type 2 Diabetes Findings Reported from Regeneron..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
11/26 Johnson & Johnson approaches Actelion about takeover deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/07 ET TU, DONALD? DRUGS DIVE : What's Going On, And What's Next
12/05 BIOTECH FORUM DAILY DIGEST : Biotech Has Tough Week; Will Conference Buoy Immuno..
12/02 TRUMP AS REAGAN 2.0 - THE ANALOGY IS : What's Next
12/01 Significant Upside Potential For Ophthotech Before Phase 3 Fovista Readout
12/01 ALLERGAN : Low Enough To Like, Or Valeant-Lite?
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 451 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, CEO & Class I Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Class I Director & Chief Scientific Officer
Charles A. Baker Independent Class III Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-33.32%38 181
AMGEN, INC.-13.02%105 034
GILEAD SCIENCES, INC.-28.08%95 884
CELGENE CORPORATION-5.93%87 334
ACTELION LTD45.20%22 148
VERTEX PHARMACEUTICALS..-40.14%18 682
More Results